Company / R&D Expense
Summit Therapeutics Inc. R&D Expense History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$537.7M
FY2025
5-year range
$59.5M / $537.7M
FY2021-FY2025
Trend
+256.6%
vs FY2024
Sector context
#33 of 210
Health Care
What the data says
R&D Expense changed +257% YoY in FY2025, a notable deviation from the 7-year average annual change of +64%.
Based on SEC 10-K filings.
$538M in FY2025 with a 5-year CAGR of +58.8%. Top quartile in the Health Care sector.
Improved from $59M to $538M over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +84.7%
- 5-Year CAGR
- +58.8%
- 10-Year CAGR
- -
Sector benchmark
Top 16% in Health CareTop 16% of 210This company $537.7M Sector average $644.1M
▼
-16.5% below sector average
Key checks
Key Insights
- 5-year CAGR of +58.8%, indicating consistent growth.
- In FY2025, r&d expense increased 256.6% year-over-year.
- Ranks #33 out of 210 companies in the Health Care sector.
- Lowest r&d expense in the period was in FY2019.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $537.7M | +256.6% |
| FY2024 | $150.8M | +153.5% |
| FY2023 | $59.5M | -30.3% |
| FY2022 | $85.4M | +0.0% |
| FY2021 | $85.4M | +60.2% |
| FY2020 | $53.3M | +33.8% |
| FY2019 | $39.8M | -23.4% |
| FY2018 | $52.0M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026